Research graph
References from Efficacy and safety of extended-release carbidopa–levodopa (IPX203) versus immediate-release carbidopa–levodopa for Parkinson's disease: A systematic review. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
10.1136/bmjmed-2023-000705
10.1136/bmjmed-2023-000705 · External reference
Unresolved reference
External reference
10.1002/mds.870080507
10.1002/mds.870080507 · External reference
10.1002/mds.25260
10.1002/mds.25260 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Off-time treatment options for Parkinson’s disease
2023 · External reference
Single-dose pharmacokinetics of madopar HBS in patients and effect of food and antacid on the absorption of madopar HBS in volunteers
1987 · External reference
Pharmacokinetics and bioavailability of sinemet CR: a summary of human studies
1989 · External reference
10.1016/j.prdoa.2023.100197
10.1016/j.prdoa.2023.100197 · External reference
10.1001/jamaneurol.2023.2679
10.1001/jamaneurol.2023.2679 · External reference
10.1097/wnf.0000000000000314
10.1097/wnf.0000000000000314 · External reference
Pharmacodynamics, efficacy, and safety of IPX203 in Parkinson disease patients with motor fluctuations
2019 · External reference
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
2021 · External reference
Rob 2: a revised tool for assessing risk of bias in randomised trials
2019 · External reference
10.1007/s10072-025-08692-9
10.1007/s10072-025-08692-9 · External reference
10.1007/s00702-007-0773-x
10.1007/s00702-007-0773-x · External reference
10.1016/s1471-1931(00)00029-x
10.1016/s1471-1931(00)00029-x · External reference
Unresolved reference
External reference
